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Tumors have evolved elaborate mechanisms for evading immune detection, such as production 
of immunoinhibitory cytokines and down-regulation of major histocompatibility complex 
(MHC) expression. We have studied PAX3-FKHR as an example of an oncogenic fusion protein 
associated with an aggressive metastatic cancer. We show that PAX3-FKHR alters expression 
of genes that are normally regulated by Janus kinase/signal transducer and activator of 
transcription (STAT) signaling pathways. This occurs as a result of a specific interaction 
between PAX3-FKHR and the STAT3 transcription factor, which results in a dramatic 
reduction in tumor MHC expression, and an alteration in local cytokine concentrations to 
inhibit surrounding inflammatory cells and immune detection. Collectively, these data show 
that an oncogenic transcription factor can promote tumor growth and tissue invasion while 
inhibiting local inflammatory and immune responses. This is the first time that an 
immunomodulatory role has been described for an oncogenic fusion protein.
 
Rhabdomyosarcoma (RMS) is an aggressive
tumor resembling developing skeletal muscle
that predominantly affects children (1). PAX3-
FKHR is an oncogenic fusion protein and is
specifically associated with the alveolar subtype
of RMS (ARMS), which is a more aggressive
tumor than the embryonal form (ERMS)
that lacks PAX3-FKHR and is less likely to
be metastatic or locally invasive (2–5).
PAX3-FKHR can transform NIH3T3 cells
and chicken embryo fibroblasts (6, 7), whereas
experimentally induced expression of PAX3-
FKHR in ERMS cells has been shown to result
in more rapid tumor growth and local tissue
invasion (8). PAX3-FKHR has recently been
shown, when expressed in mouse Myf6 express-
ing developing myoblasts, to promote forma-
tion of tumors that histologically and im-
munohistochemically resemble human ARMS
(9). PAX3-FKHR contains the NH
 
2
 
-terminal
DNA binding domain of PAX3 fused in frame
with the COOH-terminal transactivation do-
main of FKHR. PAX3-FKHR confers strong
transcriptional activation of known PAX3 target
genes mediated by the FKHR transcriptional
activation domain (10–12).
A component of cancer progression is the
failure of the host immune response to recognize
tumor cells. STATs are a family of transcription
factors that are activated by tyrosine phosphor-
ylation in response to a variety of growth fac-
tors and cytokines. Specifically for IFN-
 
 
 
, sig-
naling occurs through IFN-
 
 
 
 receptor subunits
1 and 2 (IFN-
 
 
 
R1 and -2), which interact
with JAK1 and JAK2 and predominantly activate
STAT1. For IL-6, the IL-6 receptor interacts
predominantly with JAK1 and predominantly
activates STAT3 (13). The STATs undergo
homo- and heterodimerization, bind DNA,
and induce expression of target genes. Moreover,
there is cross talk between IL-6 and IFN-
 
 
 
 sig-
naling; e.g., IL-6 will trigger an IFN-
 
 
 
 response
predominantly via STAT1 in the absence of
STAT3 (14, 15). Recently, aberrant activation
of STAT3 has been recognized in a variety of
human cancers to cause a negative regulation
of inflammatory responses and an inhibition of
cross talk between innate and adaptive immu-
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nity, thereby allowing unrestrained tumor growth (16–18).
STAT3 activation as a primary oncogenic event has not,
however, been described and has been assumed to result
from deregulation of upstream kinases and growth factors.
We provide evidence that a primary transforming onco-
genic event (generation of PAX3-FKHR fusion protein) also
contributes to tumor immune escape through a novel inter-
action with STAT3. The presence of the PAX3-FKHR–
STAT3 complex alters transcription of known STAT target
genes, causing an immunoinhibitory tumor environment.
 
RESULTS
PAX3-FKHR induces transcriptional activation 
and repression in RMS cells
 
To investigate how PAX3-FKHR fusion alters gene expres-
sion, we transfected two different ERMS cell lines (RD and
76-9) with PAX3-FKHR and generated stable clones. 76-9
are murine RMS cells (19) that form tumor xenografts that
resemble the embryonal histological type and express the
myogenic marker MyoD1 (unpublished data). RD is a hu-
man ERMS cell line. PAX3-FKHR protein activity in 76-9
and RD stable clones was quantified in transient transfection
assays. Six clones (76-9–P3F-C23, 76-9–P3F-C24, and RD-
P3F clones 2, 5, 6 and 18) were chosen and showed levels
of PAX3-FKHR protein activity of 
 
 
 
30% of the level of
SCMC-RM2 and RH30, cell lines that both endogenously
express PAX3-FKHR (Fig. 1 A).
We have previously shown that transfecting RD cells
with 
 
PAX3-FKHR
 
 results in enhancement of locally inva-
sive tumor growth in vivo (8). In matrigel invasion assays,
76-9–P3F-C23 and 76-9–P3F-C24 cells were significantly
more invasive than control vector transfected 76-9 (P 
 
 
 
0.005; Fig. 1 B). Therefore, ectopic PAX3-FKHR expres-
sion causes a phenotypic change in ERMS cells consistent
with the more aggressive phenotype of ARMS. PAX3-
FKHR transcriptional targets in 76-9 cells were determined
by oligonucleotide microarray gene expression analysis. 31
genes were significantly up-regulated and 69 genes were
down-regulated by PAX3-FKHR (P 
 
  
 
0.05 by 
 
t
 
 test; see
Table I for a summary; for a complete gene list, see Tables
S1 and S2, available at http://www.jem.org/cgi/content/
full/jem.20050730/DC1). For three genes tested (
 
pai
 
,
 
 xmr
 
,
and 
 
crabp1
 
), the expression changes in Northern blot analysis
were equivalent to those seen in microarrays (Fig. 1 C). We
were further convinced of the validity of the gene list be-
cause of the up-regulation of 
 
IGF2
 
, a known PAX3-FKHR
target gene that is frequently overexpressed in RMS (20–22)
and was induced five- to sixfold by PAX3-FKHR in 76-9
cells (Table I).
 
PAX3-FKHR down-regulation of target genes in human 
and murine cells
 
To determine if the transcriptional targets for PAX3-FKHR
that we had detected in 76-9 cells were similarly regulated in
a different cellular environment, we investigated expression
patterns of two down-regulated genes (
 
PAI-1
 
 and 
 
MHC class
1
 
) in human ERMS (RD) cells stably transfected with
 
PAX3-FKHR
 
. Although PAX3-FKHR causes only a mod-
est reduction in 
 
MHC class1
 
 mRNA, the presence of the fu-
sion completely abrogated its surface expression in RD as
well as in 76-9 cells (Fig. 2 A), possibly because of the con-
current inhibition of transporter associated with antigen pro-
cessing (TAP) transcription (Table I). PAI-1 inhibits tis-
sue invasion by inhibiting urokinase plasminogen activator,
which is involved in RMS cell migration (23), and we have
previously shown that RD cells transfected with 
 
PAX3-
FKHR
 
 have enhanced tissue invasion (8). In agreement with
data generated in the murine cells, RD cells (wild type or
Figure 1. PAX3-FKHR causes both up- and down-regulation of 
target genes. (A) PAX3-FKHR protein function in 76-9 and RD cells stably 
transfected with pBK-CMV-P3F as determined by transient transfection 
assays using the specific PAX3 reporter plasmid PRS-9 linked to CAT. This 
contains six direct repeats of the PAX3 paired domain and homeodomain 
consensus sequences upstream of a CAT reporter. CAT activity is plotted in 
arbitrary units   SEM of triplicate samples. This assay is representative of 
four separate experiments. (B) Matrigel invasion assay to show that PAX3-
FKHR increases the invasive ability of 76-9 cells. Percent invasion was cal-
culated as: (number of invasive cells / total number of cells)   100. Mean 
values   SEM of quadruplicate samples are plotted. PAX3-FKHR–expressing 
76-9–P3F-C24 cells (and 76-9–P3F-C23 cells; not depicted) were significantly 
more invasive than 76-9–CMV cells. *, P   0.005 by t test. Data are repre-
sentative of three separate experiments. (C) Northern blot analysis of vector 
(CMV) and PAX3-FKHR–transfected (C23) 76-9 cells. (right) Fold changes 
in mRNA expression in C23 relative to CMV are shown for the Northern 
blots (and the microarrays). (left) Two replica blots were probed. Band 
intensities were normalized relative to actin. 
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vector transfected) expressed high levels of PAI-1 protein,
but the presence of PAX3-FKHR caused a dramatic reduc-
tion, and cell lines endogenously expressing PAX3-FKHR
had low PAI-1 protein (Fig. 2 B).
Interestingly, a large proportion (29 out of 69) of the
genes repressed by PAX3-FKHR in the microarray screen
were known target genes of STAT1 and/or STAT3 that
were regulatable by IFN-
 
  
 
and/or IL-6 via JAK/STAT sig-
naling cascades. (Table I and Tables S1 and S2) (24). We
postulated that PAX3-FKHR might function in part by in-
hibition of transcription downstream from IL-6 and/or IFN-
 
 
 
receptors. We began by confirming that MHC class I and
PAI-1 were IFN-
 
 
 
 targets in RD cells (Fig. 2, C and D). In
RD cells transfected with PAX3-FKHR, addition of IFN-
 
 
 
did induce MHC expression, but the maximal expression
was significantly less than was seen in vector-transfected cells
(Kolmogorov-Smirnov test between RD-P3F#6 
 
  
 
IFN-
 
 
 
and RD-CMV 
 
 
 
 IFN-
 
 
 
, P 
 
  
 
0.001; Fig. 2 C). More strik-
ingly, there was no substantial increase in PAI-1 after addi-
tion of IFN-
 
 
 
 in the presence of PAX3-FKHR (Fig. 2 D).
The effect of PAX3-FKHR on PAI-1 protein in RD cells
was mirrored in changes at the RNA level, where the pres-
ence of PAX3-FKHR completely abrogated IFN-
 
 
 
 response
(Fig. 2 E). Of note, the IFN-
 
 
 
 targets down-regulated by
PAX3-FKHR in Table I have known roles of inhibition of
tumor growth through generation of inflammatory responses
(e.g. CXCL10, CCL5, MHC, and TAP). We reasoned that
if interference with transcription downstream from IFN-
 
 
 
/
IL-6 signaling was a function of PAX3-FKHR, then genes
that are normally inhibited by IFN-
 
 
 
 should be up-regulated
 
Table I.
 
Genes significantly up- and down-regulated more than twofold by PAX3-FKHR in 76-9 cells
 
Gene
GenBank
accession number
Affymetrix
identity code Description
CMV
fold change
C23
fold change
C24
fold change
 
p-value
 
IGF2
 
X71922 98623_g_at Insulin-like growth factor 2 1 5.02 6.03
 
 
 
0.001
 
PLA2
 
AA408341 94665_at Phospholipase A2 group 5 1 3.74 4.44
 
 
 
0.001
 
PLA2
 
U66873 101328_at Phospholipase A2 group 5 1 3.70 3.05 0.002
 
TGOLN2
 
D50032 93882_f_at Trans-Golgi network protein 2 1 2.33 2.22
 
 
 
0.001
 
XMR
 
X72697 102818_at Xlr-related, meiosis regulated gene 1 6.88 7.19
 
 
 
0.001
 
CSTF2T
 
AI854864 104126_at Cleavage stimulation factor,
3
 
 
 
 pre-RNA subunit
1 2.06 2.36 0.002
 
TRAM1
 
AA763937 160936_at Translocating chain-associating
membrane protein 1
1 2.65 2.89
 
 
 
0.001
 
AKR1C13
 
AB027125 95015_at Aldo-keto reductase family 1,
member C13
1 2.13 3.08
 
 
 
0.001
 
COL3A1
 
X52046 98331_at Collagen 
 
 
 
 I, type 3 subunit 1 3.31 4.06
 
 
 
0.001
IFN-regulated
genes
 
G1P2
 
X56602 98822_at IFN-
 
 
 
–inducible protein 1 0.25 0.20
 
 
 
0.001
 
IFI204
 
M31419 98465_f_at IFN-activated gene 204 1 0.15 0.11
 
 
 
0.001
 
ISGF3G
 
U51992 103634_at IFN-stimulated gene factor 3 
 
 
 
1 0.23 0.17
 
 
 
0.001
 
H2-K
 
V00746 93120_f_at MHC class I, histocompatibility 2,
K region
1 0.49 0.49 0.002
 
H2-D1
 
X52490 101886_f_at Histocompatibility 2, D region locus 1 and 
 
 
 
(2)
microglobulin
1 0.59 0.5 0.003
 
TAP1
 
U60020 103035_at Transporter associated with antigen processing
1
1 0.42 0.46 0.003
 
CXCL10
 
M33266 93858_at Chemokine (C-X-C motif) ligand 10
(IFN-inducible protein 10)
1 0.36 0.25 0.001
 
STAT1
 
U06924 101465_at Signal transducer and activator of transcription 
1
1 0.31 0.41 0.004
 
CCL5
 
AF065947 98406_at Chemokine ligand 5 (regulated on activation,
normal T cell expressed and secreted)
1 0.41 0.26 0.002
Additional
genes
 
CRABP1
 
X15789 98108_at Cellular retinoic acid binding protein 1 0.52 0.41 0.002
 
PAI1
 
M33960 94147_at Plasminogen activator inhibitor 1 1 0.26 0.34 0.001
 
Data are presented as expression level relative to the parental cell line (CMV). The expression level of each target gene is set as 1 in the CMV cells. The values for each cell line 
are the means of three probe arrays. The GenBank/EMBL/DDBJ accession numbers from which the oligonucleotide sequences were drawn are shown. p-values were determined 
by 
 
t
 
 test. 
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by PAX3-FKHR and contribute to tumor progression. This
was found to be true for the chemokine receptor CXCR4
(Fig. 2 F), confirming the previously recognized role for this
protein in promoting ARMS metastasis downstream from
PAX3-FKHR (25).
 
PAX3-FKHR interacts physically with STAT3 to modify 
STAT3 transcription
 
We hypothesized that PAX3-FKHR might interact with
STAT3 because (a) STAT3 plays a critical role in immune
evasion in tumor cells (17); (b) it down-regulates the proin-
flammatory cytokines CCL5 (regulated on activation, nor-
mal T cell expressed and secreted) and IP10 that we show to
be down-regulated by PAX3-FKHR (17); and (c) FKHR it-
self has recently been shown to interact with STAT3 and to
be a transcriptional coactivator for it (26). Moreover, be-
cause most ARMS tumors express a fusion gene with PAX3
or PAX7 fused in frame with a FOXO1 family member
(27), we reasoned that FKHR is likely to contribute to the
function of PAX3-FKHR over and above its contribution of
a strong transcriptional activation domain.
We initially investigated a putative interaction with
STATs by using a 4-hydroxy-tamoxifen (4HT)–inducible es-
trogen receptor–tagged PAX3-FKHR construct stably trans-
fected in RD cells (Fig. 3 A). After addition of 4HT, the es-
trogen receptor antibody coimmunoprecipitated STAT3 and
PAX3-FKHR in RD cells expressing PAX3-FKHR–ER
(Fig. 3 B) but did not precipitate STAT3 in the absence of
4HT or in RD cells transfected with an empty vector (not
depicted). Interestingly, in the absence of 4HT, the anti-
STAT3 antibody repeatedly failed to immunoprecipitate
STAT3 in PAX3-FKHR–ER–transfected RD cells (Fig. 3
Figure 2. PAX3-FKHR substantially down-regulates PAI-1 and 
MHC class I protein expression in mouse and human RMS cells. (A) FACS 
analysis of MHC class I surface expression. The dotted line represents the 
secondary antibody alone, and the continuous line represents staining 
with anti–MHC class I. The staining is representative of four separate 
experiments. (B) Western blot analysis examining PAI-1 protein expression 
in RD-CMV and RD-P3F clones and in several human RMS cell lines. In a 
longer exposure, very faint bands can be detected in the lanes corresponding 
to the RD-P3F clones 6, 2, and 18. The RMS type and the expression of
endogenous PAX3 and PAX3-FKHR RNA (determined by Northern blot;
not depicted) for each cell line is indicated. A, ARMS; E, ERMS. (C) FACS 
analysis of MHC class I surface expression on cells cultured in the presence 
of 20 ng/ml IFN-  for 48 h. The dotted line represents the secondary anti-
body alone, the continuous line represents MHC class I expression in the 
absence of IFN- , and the shaded histogram represents MHC class I in the 
presence of 20 ng/ml IFN- . FACS staining is representative of three separate 
experiments. Mean fluorescence intensities from the FACS plots are also 
indicated. Error bars   SEM. (D) Western blot of PAI-1 expression after 
treatment with 20 ng/ml IFN-  for 48 h is representative of two indepen-
dent experiments. PAI-1 was detected at a molecular mass of  47 kD, and 
 -tubulin expression was used as a loading control. (E) PAI-1 expression 
determined by quantitative RT-PCR. Expression is normalized to GAPDH 
and expressed relative to RH30 expression. Error bars   SEM of triplicate 
estimations. (F) FACS histograms of CXCR4 surface expression. The dotted 
line represents isotype control antibody, and the continuous line represents 
anti-CXCR4 antibody. 
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B), even though STAT3 could readily be precipitated from
vector-transfected RD cells (not depicted). This suggested
that cytoplasmic PAX3-FKHR–ER might sequester STAT3
in the cytoplasm in an inaccessible form. To determine the
region of PAX3-FKHR that interacts with STAT3, we gen-
erated myc epitope–tagged full-length PAX3-FKHR and
truncated PAX3 lacking all of the FKHR components of the
fusion. These myc-tagged fusions were transiently transfected
into 293T cells, and high-level expression was obtained (Fig.
3 C, left). After transfection with full-length PAX3-FKHR,
both myc and STAT3 antibodies were reproducibly able to
immunoprecipitate STAT3, but this coimmunoprecipitation
could not be performed in untransfected 293T cells or in
293T cells transfected with truncated PAX3 (Fig. 3 C). The
interaction was specific for STAT3 because STATs 2, 4, and
6 failed to coprecipitate with PAX3-FKHR (Fig. 3, right).
However in both RD and 293T cells transfected with
PAX3-FKHR, precipitation of PAX3-FKHR weakly copre-
cipitated STAT5, suggesting a weak interaction between
these proteins (Fig. 3, B and C). To confirm that this inter-
action also occurs in ARMS cell endogenously expressing
PAX3-FKHR, we were able reproducibly to coimmunopre-
cipitate PAX3-FKHR and STAT3 in RH30 cells that en-
dogenously express PAX3-FKHR (Fig. 3 D). The intensity
of the STAT3 band immunoprecipitated by the PAX3 anti-
body in Fig. 3 D appears weaker than that precipitated by the
myc epitope antibody in Fig. 3 C because the PAX3 anti-
body is very inefficient at immunoprecipitation.
Figure 3. PAX3-FKHR interacts with STAT3. (A) Transient transfection 
assay using PRS9-CAT reporter showing specific inducible activity of 
PAX3-FKHR in clone 15 on addition of 4HT. Error bars   SEM of triplicate 
transfections. (B) Coimmunoprecipitation of STAT3 with estrogen receptor–
tagged PAX3-FKHR is seen only in presence of 4HT. The IP is representative 
of three separate experiments. The high molecular mass band of  200 kD 
shown here was not seen in all replicate experiments. (bottom) Replica 
blot probed with STAT5. (C) Immunoprecipitations from 293T cells trans-
fected with PAX3-FKHR, truncated PAX3-FKHR lacking FKHR regions, or 
empty vector. (left) Lysates are detected with an anti-PAX3 antibody. Immu-
noprecipitates are detected with an anti-STAT3 antibody. The IP data are 
representative of three separate experiments. (right) Replica blots from the 
same transfections probed with antibodies against STATs 2 (113 kD), 4 (81 kD), 
5 (95 kD), and 6 (100 kD). No staining with STATs 2, 4, or 6 was observed when 
the membrane was subject to longer exposures. (D) Coimmunoprecipitation 
experiment to show that an anti–NH2 terminus PAX3 antibody and anti-
STAT3 antibody are both able to precipitate STAT3 from RH30 cells. The 
blot is representative of two independent experiments. 
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The presence of PAX3-FKHR causes the STAT3-dependent 
generation of immunoinhibitory secreted factors
We hypothesized that the range of altered transcription in-
duced by PAX3-FKHR that we had identified might make
the tumor environment more immunoinhibitory. We used
DC activation/maturation as a marker of the tumor cytokine
environment. For these experiments, we collected condi-
tioned medium (CM) from PAX3-FKHR–expressing and –non-
expressing cell lines grown in the presence or absence of a
specific phosphopeptide inhibitor of activated STAT3 (28).
Human DCs were generated from monocytes in the presence
of CM, and activation was determined by flow cytometry af-
ter staining with HLA-DR and CD86. CM from RD cells
stably transfected with estrogen-tagged PAX3-FKHR (RD-
P3FER clone 15) inhibited DC activation only after addition
of 4HT. This inhibition was STAT3 dependent because the
Figure 4. The presence of PAX3-FKHR causes the STAT3-dependent 
generation of immunoinhibitory secreted factors. (A–E) Flow cytometric 
analysis of HLA-DR and CD86 expression on viable CD11c -gated DCs 
generated in CM from various cell lines (RD Vect /  4HT and RD P3F-ER /  
4HT; 293T transfected with combinations of empty vector, truncated 
PAX3, PAX3-FKHR, PAX3-FKHR mutants, dominant negative STAT3, or 
siRNA against STAT3; and RH18 or RH30) 24 h after KLH activation. As 
indicated, conditioned media were obtained after growth of cell lines in 
the presence of a specific STAT3 inhibitory phosphopeptide (PY*) or control 
nonphosphorylated peptide (PY). G48S, paired domain mutant PAX3-FKHR; 
N269, homeodomain mutant of PAX3-FKHR; STAT3- , dominant-negative 
form of STAT3. Data are the representative result of between two and 
three independent experiments. Conditioned media were collected from 
confluent cell lines 48 h after passaging. All FACS plots have logarithmic 
scales. Percentages refer to the percentage of CD11c-positive cells in the 
top right quadrant or indicated gates. (F) Stat-3 expression in tumor cells 
increases IL-10 cytokine production. Detection of human IL-10 secretion 
in tumor cells expressing inducible P3F-ER. Results are presented as the 
SEM of triplicate samples and are representative of two independent 
experiments.JEM VOL. 202, November 21, 2005 1405
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effect was completely lost in the presence of the phosphopep-
tide inhibitor but not an unphosphorylated control peptide
(Fig. 4 A). Moreover, the inhibition was specific for PAX3-
FKHR because CM from vector transfected RD cells was
unaffected by 4HT and anti-STAT3 phosphopeptide in
terms of the ability to inhibit DC activation (Fig. 4 A). To as-
sess whether this PAX3-FKHR effect could be reproducibly
demonstrated in a different cell environment, we analyzed
CM from 293T cells transiently transfected with full-length
or truncated PAX3-FKHR (see Fig. 3 C for levels of expres-
sion of transfected proteins). Expression of full-length but not
truncated PAX3-FKHR almost completely inhibited DC ac-
tivation, and this inhibition was STAT3 dependent because it
was completely reversed by the specific phosphopeptide in-
hibitor but not by control peptide (Fig. 4 B). We next con-
firmed that the inhibitory effects of the phosphopeptide in-
hibitor could be repeated using other methods of specific
STAT3 down-regulation. Both cotransfection with small in-
terfering RNA (siRNA) targeting STAT3 and STAT3-  (a
dominant-negative form of STAT3) (17, 29) specifically and
completely prevented PAX3-FKHR–mediated inhibition of
DC maturation (Fig. 4 C). We hypothesized that if PAX3-
FKHR were interacting with STAT3 through the FKHR
component of the fusion, then its effect on DC maturation
might be independent of transcription of PAX3 target genes.
To test this, we transfected 293T cells with mutant forms of
PAX3-FKHR containing point mutations in the paired do-
main (G48S) and homeodomain (N269) (6, 30). The paired
Figure 5. PAX3-FKHR suppresses local inflammatory and immuno-
logical responses and causes more rapid in vivo growth rate in 
immunodeficient mice. Tumor growth rates and tumor infiltrating cells 
of PAX3-FKHR expressing (C23) or control (CMV) cells grown in immuno-
deficient (A) or syngeneic C57BL/6 (B) mice. Each line represents the tumor 
growth curve of an individual animal. Tumor-infiltrating cells were deter-
mined by FACS analysis. Histograms indicate the percentage of total cells 
that were gated as viable cells for the analysis of tumor-infiltrating cells. 
Closed bars, tumors from vector-transfected 76-9 cells; open bars, tumors 
derived from 76-9–P3F-C23 cells. For DC activation analysis, CD11c cells 
were gated, and respective activation markers were enumerated. Error 
bars   SEM of four tumors per group.PAX3-FKHR–STAT3 INTERACTION | Nabarro et al. 1406
domain mutant, which has no transcriptional activity on
PAX3 targets, had a wild-type effect on DC maturation inhi-
bition (Fig. 4 D). The homeodomain mutant, however, had
only  40% of the effect on inhibition of DC maturation
(Fig. 4 D), which was consistent with a reported role of the
homeodomain of PAX3-FKHR in mediating functionally
important protein–protein interactions (6, 30). Finally, we
confirmed that ARMS cell lines endogenously expressing
PAX3-FKHR (RH30 and SCMC) also produce an immu-
noinhibitory microenvironment that inhibits DC activation
in a STAT3-dependent manner, whereas RH18 conditioned
media (PAX3-FKHR negative) does not substantially affect
DC maturation (Fig. 4 E and not depicted for SCMC).
Therefore, PAX3-FKHR interacts with STAT3 to induce
secretion of factors that can directly alter local DC activation.
We next analyzed IL-10 secretion from PAX3-FKHR–
expressing cells as a candidate cytokine for the PAX3-
FKHR–mediated effects on DC maturation. RD cells stably
transfected with estrogen-tagged PAX3-FKHR produce in-
creased amounts of IL-10 in a STAT3-dependent manner
only in the presence of 4HT, whereas 4HT has no effect on
IL-10 production by vector-transfected RD cells (Fig. 4
F). RH30 cells endogenously expressing PAX3-FKHR also
produce IL-10 in a STAT3-dependent manner (Fig. 4 F).
PAX3-FKHR suppresses local inflammatory and 
immunological responses and causes more rapid in vivo 
growth in immunodeficient mice
To determine if the PAX3-FKHR–induced local cytokine
alterations observed in vitro are sufficient to alter host re-
sponses to tumors, we analyzed the inflammatory cell infil-
trates of subcutaneous tumor xenografts. We have observed
in experiments in immunocompetent C57BL/6 mice that
growth of PAX3-FKHR–expressing tumors is associated
with a specific anti-PAX3 cellular immune response (unpub-
lished data). We therefore performed the initial experiments
using RAG / /common   chain / /complement C5 / 
mice that have deficiency of functional T cells, B cells, and
NK cells (unpublished data). We analyzed intratumoral in-
flammatory cells by flow cytometry after disaggregating tu-
mors with collagenase. Importantly, the percentage of viable
cells was identical between PAX3-FKHR–expressing and
–nonexpressing cells so that the percentages of stained cells
could be extrapolated to total numbers of infiltrating cells
(Fig. 5, middle). We found considerable inhibition of intra-
tumoral DC maturation by PAX3-FKHR and a decrease in
infiltration of neutrophils and macrophages (Fig. 5 A). The
tumor growth rate of PAX3-FKHR–expressing cells was
substantially increased compared with vector-only trans-
fected cells (Fig. 5 A) even though the growth characteristics
of the paired cell lines in vitro were identical (not depicted),
which was consistent with increased in vivo growth being
secondary to decreased tumor inflammatory response.
With engraftment in syngeneic C57BL/6 mice (in which
interpretation of tumor growth rate is complicated by the
anti-PAX3 immune response) the presence of PAX3-FKHR
was associated with a considerable decrease in the numbers
of CD8- and CD4-positive infiltrating T cells and NK cells
but no difference in the number of infiltrating total NK1.1-
positive cells (NK cells plus NKT cells). These changes were
associated with a decrease in the numbers of infiltrating mac-
rophages and neutrophils and a large reduction in the matu-
ration of tumor-infiltrating DCs (Fig. 5 B). The tumor
growth rate was identical among PAX3-FKHR–expressing
and –nonexpressing tumors.
PAX3-FKHR–expressing ARMS tumors have 
an immunoinhibitory phenotype
We hypothesized that the rapid growth and local tissue de-
struction of ARMS should result in marked local inflamma-
tion. We analyzed eight PAX3-FKHR–expressing (unpub-
lished data) ARMS primary tumor biopsies and looked for
the presence of neutrophils as a marker of inflammation or
immune response. We found a mean of only 0.5 neutrophils
per 10 high power fields (range 0–2) compared with a mean
of 1.5 per 10 ERMS tumors (range 0–4; Fig. 6 A). We next
looked at the subcellular location of STAT3 in these same
PAX3-FKHR–expressing and –nonexpressing tumor sam-
ples by immunohistochemistry using a STAT3-specific anti-
body. In control tonsil (n   1) and breast carcinoma (n   2)
sections, STAT3 was largely cytoplasmic. In three ERMS
samples lacking PAX3-FKHR, STAT3 had weak staining
Figure 6. PAX3-FKHR–expressing ARMS cells have an immunoinhibi-
tory phenotype. (A) Numbers of neutrophils infiltrating PAX3-FKHR–
expressing human ARMS versus ERMS tumors. The box whisker plot shows 
the first and third quartiles, median, and range. (B) Representative image 
of STAT3 immunohistochemistry of prechemotherapy tumor biopsies or 
surgical specimens. Three representative ARMS tumors are shown with 
one ERMS case for comparison.JEM VOL. 202, November 21, 2005 1407
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and was localized in both the cytoplasm and nucleus. (Fig. 6
B). In the ARMS cases, all of which were PAX3-FKHR fu-
sion–positive, there was strong nuclear staining in five out of
five cases (Fig. 6 B), indicating high-level expression or sta-
bilization of STAT3 protein and localization in the nucleus.
DISCUSSION
It is well attested in the literature that tumors are capable
of inhibiting immunological and inflammatory responses
through mechanisms such as the production of the immu-
noinhibitory cytokine IL-10. Recently, STAT3 has been
identified as an immunoinhibitory and oncogenic transcrip-
tion factor, the activity of which is up-regulated in tumors.
Moreover, tumor cells are dependent on STAT3 for growth
(29, 31). In this paper, we identify a novel mechanism
whereby a chimeric fusion oncoprotein transcription factor
(PAX3-FKHR) that is capable of binding target DNA se-
quences through its DNA binding domain to promote ma-
lignant transformation also interacts with STAT3 transcrip-
tion factor through its FKHR-derived sequences to modify
inflammatory response to the developing tumor. The immu-
nomodulatory effect is independent of the ability of the fu-
sion protein to bind PAX3 target promoters, suggesting that
PAX3-FKHR might not bind DNA directly when in a tran-
scriptional complex with STAT3. As STAT3 is known to
activate genes as both homo- and heterodimers with other
STATs, it is likely that there are several different STAT3
target promoter recognition sequences, the binding to
which by STAT3 could be differentially regulated by PAX3-
FKHR. Further work is needed to identify the pathways by
which STAT3 regulates its target promoters and PAX3-
FKHR modifies this regulation. The possible physiologi-
cal significance of the apparent weak interaction between
PAX3-FKHR and STAT5 also needs to be tested.
Previous researchers have not identified IFN- /IL-6 tar-
gets as PAX3-FKHR–negative targets. There are two possi-
ble explanations for this. First, in a study by Khan et al. (22),
PAX3-FKHR was introduced into NIH3T3 cells that are
not myogenic, and the predominant transcriptional pattern
identified was up-regulation of a myogenic program. In our
study, the recipients are RMS cells already expressing myo-
genic genes, thereby allowing other transcriptional effects of
PAX3-FKHR to be disclosed by microarray analysis. Sec-
ond, it is possible that JAK/STAT signaling is less active in
the cell system used in the study by Khan et al., so the role of
PAX3-FKHR interacting with this signaling would be less
apparent. We have shown that PAX3-FKHR interacts with
STAT3 to alter immunological response to tumors when ec-
topically expressed in two separate myogenic tumor cell
lines. We have also shown that PAX3-FKHR interacts with
STAT3 in the physiological setting of RH30 ARMS cells
and that blocking STAT3 reverses RH30 cells’ inhibition of
DCs. Further work is needed to define the mechanism and
extent of transcriptional activation and repression by the
PAX3-FKHR–STAT3 complex in ARMS cells and tumors
and to define the extent of the contribution, if any, of
STAT3 activation to transcription of PAX3-FKHR tar-
gets from PAX3 target promoters. However, experimental
down-regulation of PAX3-FKHR in ARMS cells to dem-
onstrate reversal of changes in STAT3 targets will be chal-
lenging because of the additional survival properties of
PAX3-FKHR, which means that its down-regulation results
in apoptosis (32, 33).
Previous researchers have demonstrated that unphosphor-
ylated FKHR binds STAT3 and is a cofactor for transcrip-
tional activation of the STAT3 target promoter  2-macro-
globulin (26). FKHR activation of STAT3 is negatively
regulated by its phosphorylation after AKT activation. It is
not known how FKHR differentially interacts with STAT3
and STAT1 homo- and heterodimers. It is interesting to
speculate that the normal negative regulation on FKHR by
AKT, in terms of its STAT3 coactivation, is missing from
the PAX3-FKHR–STAT3 complex because of loss of a crit-
ical tyrosine residue in the NH2 terminus of FKHR. De-
tailed experimental approaches will be required to determine
the target promoters for the PAX3-FKHR–STAT3 com-
plex, whether STAT1 transcription is affected directly or in-
directly, and the mechanism of regulation of the complex by
upstream signaling. Similarly, the requirement of STAT3 to
be phosphorylated in order to be activated when bound by
PAX3-FKHR needs to be determined. Two aspects of our
data provide some preliminary clues regarding mechanism.
First, the presence of PAX3-FKHR seems to be associated
with a largely nuclear localization of PAX3-FKHR. Sec-
ond, PAX3-FKHR lacking PAX3 transcription function has
identical effects on DC maturation. These data are consistent
with a model in which PAX3-FKHR stabilizes STAT3 in
the nucleus and acts (like FKHR) as a transcription activator.
In the in vivo setting we have shown that the PAX3-
FKHR–STAT3 interaction causes, in common with STAT3,
a marked inhibition of activation of DCs. This inhibition is
mediated by secreted factors and is dependent on STAT3
(Fig. 4). The specific STAT3-blocking phosphopeptide used
in these experiments functions by binding the SH2 domain
and preventing dimerization with other STATs (29), sug-
gesting that PAX3-FKHR, like FKHR (27), may form a
complex with STAT dimers to alter STAT transcription.
Further work is needed to determine if and how PAX3-
FKHR specifically alters transcription of different STAT
dimers on different target promoters.
In immunodeficient mice lacking functional B cells, T
cells, or NK cells, there is a reduction of macrophage and
neutrophil numbers, suggesting inhibition of innate immune
responses and inflammation. In this context it is of interest
that the presence of PAX3-FKHR is only associated with
enhanced tumor growth rates, although growth in vitro is
unaffected. A possible explanation for the lack of enhanced
growth rate in syngeneic mice is that the presence of PAX3-
FKHR itself may paradoxically render the tumors more sen-
sitive to immune detection by cellular anti-PAX3 responsesPAX3-FKHR–STAT3 INTERACTION | Nabarro et al. 1408
or NK killing secondary to reduction in MHC expression
(unpublished data). Other progrowth factors, such as the
STAT3 target VEGF, may also contribute to enhanced
growth in the in vivo setting. In future studies, it will be im-
portant to show which other oncogenic functions of STAT3
(inhibition of apoptosis, proliferation, inhibition of differ-
entiation, and angiogenesis) are also stimulated by PAX3-
FKHR in a STAT3-dependent function. If some or all of
these components of the transformed phenotype are active
in RMS, then development of agents that specifically block
the PAX3-FKHR–STAT3 interaction could be of therapeu-
tic potential with minimal expected toxicity.
We have shown for the first time that an oncogenic fu-
sion protein transcription factor can have a dual function in
malignant progression through binding its own target pro-
moters and immune evasion through interaction with JAK-
STAT signaling. Down-regulation of MHC and production
of immunoinhibitory cytokines such as IL-10 are well known
characteristics of tumor cells that are thought to be essential
for prevention of inflammation at sites of tissue injury. This
in turn might inhibit the detection of tumor-specific anti-
gens, such as fusion oncoproteins themselves. PAX3-FKHR
has been recently shown to be an initiating event in ARMS
development (9), which suggests that the tumor has, from
the time of its initial development, developed sophisticated
mechanisms to prevent its own immune detection. If similar
mechanisms can be shown to exist in other tumor types, the
implication will be that targeting of the critical oncogene
could reverse its immune evasion mechanism.
MATERIALS AND METHODS
Plasmids and cloning. The PAX3-FKHR cDNA cloned into pBK-
CMV vector has been described previously (8) and is here called pBK-
CMV-P3F. PRS9-CAT was a gift from J. Bennicelli (University of Penn-
sylvania, Philadelphia, PA). The control vectors for transient transfections
were pGL3 luciferase, pRL-TK, and pSV- -galactosidase. P3F-ER was
made by cloning the modified estrogen receptor ER (34) to the COOH
terminus of PAX3-FKHR in pBK-CMV. For transient transfections of
PAX3-FKHR or a truncated PAX3 in 293T cells, the full-length PAX3-
FKHR cDNA or PAX3 up to the breakpoint with FKHR had an myc
epitope tag added to the COOH terminus and were ligated into a lentivirus
vector LNT/SffvMCS/ccdB under the regulation of the WPRE to give
high level expression. The PAX3-FKHR mutants G48S and N269 (30)
were gifts from F. Barr and J. Xia (University of Pennsylvania, Philadelphia,
PA). The Stat3-  construct was a gift from T. Wang (Johns Hopkins Uni-
versity, Baltimore, MD). siRNA targeting STAT3 and corresponding nega-
tive control siRNA comprising a mixture of nonspecific target sequences
were purchased from Upstate Biotechnology.
Microarray, Northern blotting, and RT-PCR. Total RNA was iso-
lated from triplicate independent cultures of 76-9–CMV, C23, and C24
cells. Preparation of labeled cRNA, hybridization to MG-U74 chips, and
scanning were performed according to Affymetrix guidelines (Affymetrix,
Inc.). Using Genespring 4.2.1 software, data for each target gene was nor-
malized relative to the gene’s mean intensity in 76-9–CMV cells. A filter
identified genes that showed greater than a twofold difference in intensity in
C23 and C24 relative to the mean intensity of CMV. For Northern blots,
total RNA was electrophoresed on 1% formaldehyde agarose gels and trans-
ferred to Hybond-N membranes (GE Healthcare) and hybridized in Ul-
trahyb solution (Ambion) with the relevant radioactively labeled DNA
probe according to the manufacturer’s instructions. PAI-1 mRNA expres-
sion was determined by quantitative real-time RT-PCR using a genetic an-
alyzer (ABI7000; Applied Biosystems) and an assay (Hs00167155_m1;
Applied Biosystems) with relative expression being determined by the com-
parative method (User Bulletin 2; Applied Biosystems).
Cell culture, stable and transient transfections, and invasion assays.
76-9 cells were maintained in RPMI 1640 media. The human RMS cell
lines RH30, RH18, RMS, RD, and SCMC-RM2, as well as 293T, were
grown in DMEM supplemented with 10% FCS. To generate stable lines,
cells were transfected with Fugene 6 reagent (Roche) and selected in G418
following the manufacturer’s protocol. In normalized reporter assays, 1.75
 g of reporter and 0.25  g of control plasmids were combined. Cells were
assayed for reporter activity after 48 h using a CAT ELISA kit (Roche) and
 -galactosidase activity (Galacto-Light; Tropix). In some experiments, cells
were cultured for 48 h in 20 ng/ml recombinant human IFN-  (Pepro-
Tech). Invasion assays were performed using BioCoat matrigel invasion
chambers (Becton Dickinson) according to the manufacturer’s instructions.
Western blots and immunoprecipitation. 106 cells were lysed in 50  l
of RIPA buffer containing 1 mM sodium orthovanadate and protease in-
hibitors. Denatured whole cell lysates were electrophoresed and transferred
to Hybond-C extra membranes (GE Healthcare) in accordance with the
manufacturer’s instructions. Membranes were probed with the following
primary antibodies: PAI-1 (C-9) mAb (Santa Cruz Biotechnology, Inc.) and
 -tubulin mAb (Serotec). All HRP-labeled secondary antibodies were from
Santa Cruz Biotechnology, Inc. For immunoprecipitation, 200  l of lysate
from 5   106 cells was precipitated with 2  l of anti-STAT3 (rabbit poly-
clonal antibody; Upstate Biotechnology), anti STATs 2, 4, 5, and 6 (Santa
Cruz Biotechnology, Inc.), anti-PAX3 (N19; Santa Cruz Biotechnology,
Inc.), or antiestrogen receptor rabbit polyclonal (MC-20; Santa Cruz Bio-
technology, Inc.) antibodies using protein A sepharose (GE Healthcare) in
accordance with the manufacturer’s instructions.
Immunohistochemistry and tissue arrays. Paraffin sections of RMS
primary tumors of known PAX3-FKHR status were dewaxed and rehy-
drated. Endogeneous peroxidase was blocked by immersing the sections in
10% hydrogen peroxidase for 20 min at room temperature. Pressure cook-
ing with 10 mM citrate buffer for 4 min was used for the antigen retrieval
followed by cooling of the slides for 30 min. The primary polyclonal anti-
body is prediluted ready to use (Lab Vision). Sections were incubated at
room temperature for 60 min. The Envision HRP system for rabbit primary
antibodies (DakoCytomation) was used for the detection level. The sections
were incubated for 30 min at room temperature. Staining was with diami-
nobenzidine for 10 min to allow visualization of the antibody.
IL-10 and DC maturation assays. 5    105 RD P3F-ER cells were
plated in a volume of 2 ml, and 1  M 4HT was added for 48 h to induce
PAX3-FKHR function. For DC maturation inhibition experiments,
PBMCs were cultured in RPMI 1640 supplemented with 2% human AB
serum in the presence of 100 ng/ml GM-CSF and 10 ng/ml IL-4 (both were
obtained from PeproTech). 50% of supernatant from tumor cells was added
to DC media at day 0. Fresh medium supplemented with supernatants was
added to the culture every 2 d until day 4, at which time point 20 ng/ml of
KLH was added. DC activation was determined on day 5. For IL-10 assays,
cells were induced for 48 h by 1  M 4HT in the presence or absence of 400
 M of phosphopeptide PY*LKTK (28). IL-10 was detected in supernatants
by ELISA (BD Biosciences).
FACS staining and analysis. The following antibodies were used for
cell line staining: anti–mouse H-2Kb–PE and anti–mouse H-2Db–PE (Cal-
tag); anti–human MHC class I (Abcam); and anti–human CXCR-4–PE
(clone 12G5; R&D Systems). The following antibodies were used for DC
staining: anti-CD86–PE (clone 2331) and anti-HLA–DR–FITC (clone
G46-6; BD Biosciences). The following antibodies were used for tumor-JEM VOL. 202, November 21, 2005 1409
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infiltrating cell staining: anti-NK1.1  (clone PK136), anti-CD3 (Clone CI-
CD3), anti-CD8 (clone RH10), anti-CD4 (clone CI-CD4), anti-F4/80
(clone CI-A3-1), anti-CD11b, (clone M1/70.15), and anti-Ly6G (Gr-1;
clone RB6-8C5). For DC staining, the following murine antibodies were
used: anti-CD40 (clone 3/23), anti-CD80 (B7-1; clone RMMP-1), and
anti-CD86 (B7-2; clone RMMP-3; BD Biosciences). For DC staining, via-
ble and CD11c-positive cells were gated. Stained and fixed (1% paraformal-
dehyde) cells were analyzed using a FACS machine (Epics; Beckman
Coulter) and software (Expo32; Beckman Coulter).
In vivo growth assays. Studies were conducted in 8-wk-old C57BL/6
mice or RAG / /common    chain / /complement C5 /  (RAG / /
CGC / /C5 / ) mice. RAG / /CGC /  mice have been described pre-
viously (35), and RAG / /CGC / /C5 /  mice were generated by back-
crossing onto the A/J strain, which is naturally deficient in complement C5.
5   106 cells were resuspended in 150  l sterile PBS and injected subcuta-
neously with a 26-gauge needle into the flanks of groups of five mice. Tu-
mor size was monitored every 2 d using calipers, and the length (l) and
width (w) of the developing tumor were converted to volume using the
following equation: vol   (w2   l) / 2. Mice were killed when tumors
reached a maximum size of 1.5 cm in the largest diameter. Tumors were
mechanically disaggregated before staining for flow cytometric analysis.
Online supplemental material. Table I shows the complete list of 35 se-
quences (derived from 31 different genes) significantly up-regulated by
more than twofold in C23 and C24 cells relative to CMV. The asterisks in
the left column identify the genes that were also found to be significantly
up-regulated by more than 1.5-fold in C23 and C24 cells relative to CMV
cells in a higher stringency analysis. Table II shows the complete list of 69
sequences significantly down-regulated by more than twofold in C23 and
C24 cells relative to CMV. The asterisks in the left column identify the
genes that were also found to be significantly down-regulated by more than
1.5-fold in C23 and C24 cells relative to CMV cells in a higher stringency
analysis. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20050730/DC1.
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